Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04997993 · ClinicalTrials.gov registry record · Phase 1
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
A Phase 1 study of PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer, sponsored by Deborah Doroshow.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04997993 is a Phase 1 study of PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer that is actively recruiting participants, run by Deborah Doroshow. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04997993, a Phase 1 study of PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer, is actively recruiting participants, sponsored by Deborah Doroshow.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Leflunomide in patients with PTEN-Altered advanced solid tumors or HER2 negative breast cancer. Phase 1A objectives are to determine the safety, tolerability, and the MTD of leflunomide in patients with PTEN-Altered advanced solid malignancies and HER2 negative breast cancer. Phase 1B objective is to assess preliminary evidence of clinical activity of leflunomide in these patient populations.
Conditions Studied
Interventions
- DRUG Leflunomide
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04997993
The ClinicalTrials.gov registry entry for NCT04997993 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deborah Doroshow, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Leflunomide is the first listed.
NCT04997993 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04997993 about?
NCT04997993 is a clinical study titled "Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer". Leflunomide in patients with PTEN-Altered advanced solid tumors or HER2 negative breast cancer. Phase 1A objectives are to determine the safety, tolerability, and the MTD of leflunomide in patients with PTEN-Altered advanced solid malignancies and HER2 negative breast cancer. Phase 1B objective is t...
What is the current status of trial NCT04997993?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-12-13. Estimated completion is 2027-12.
What conditions does trial NCT04997993 study?
This clinical trial studies the following conditions: PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer.
What interventions are being tested in trial NCT04997993?
The interventions under investigation include: Leflunomide (DRUG).
Who is sponsoring clinical trial NCT04997993?
This trial is sponsored by Deborah Doroshow, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04997993 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.